Cibus Q3 2023 net loss $34.5M; cash runway only into early Q1 2024

Cibus, Inc.

2023-Q3 EPS reported -$6.33 revenue$714,000

Net loss of $34.5M ($1.59 per share) vs. $6.0M a year ago; R&D spend jumped to $17.5M.
Cash and equivalents $31.9M; company warns cash covers only planned ops into Q1 2024.
Strategic realignment & cost cuts initiated to focus on late-stage traits; no revenue reported.
Completed field trials for PSR canola, HT1/HT3 rice; returned edited germplasm to 2 of 10 customers.
UK field trials for PSR in WOSR started; EU proposed gene-editing rules seen as favorable.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cibus, Inc. reported financial results for the three months ended September 30, 2023.

Period: the three months ended September 30, 2023
Result: reported results

Exact text from the filing

On November 9, 2023, Cibus, Inc. (the “Company”) announced its financial results for the three months ended September 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Cibus, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-038235

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.